Forecast

The analysts' average price target is +89,70€ (+41,26%). The median is +89,70€ (+41,26%).

Buy	6
Hold	4
Sell	0

News Go to news feed

ANI Pharmaceuticals will appeal Delaware court ruling

A Delaware court denied ANI Pharmaceuticals’ requests for a new trial and a modified judgment in a dispute with CG Oncology. ANI plans to appeal to the Delaware Supreme Court and seeks repayment of the value of assets sold in 2010 as well as an ongoing 5% royalty on future worldwide sales of cretostimogene grenadenorepvec. The company did not disclose the scope of the assets claimed or the timetable for the appeal. » More on de.investing.com
ANI Pharmaceuticals beats Q1 2026 forecasts and raises full-year outlook

ANI Pharmaceuticals reported Q1 2026 EPS of $2.05 (expectation $1.45) and revenue of $237.5M (expectation $213.42M), a 20% increase year-over-year. Growth was driven mainly by products such as Cortrophin Gel (+42% YoY); adjusted non-GAAP EBITDA rose to $63M. The company raised its full-year guidance while the non-GAAP gross margin fell to 60.8%. The stock rose about 4.8% in pre-market trading. » More on de.investing.com
ANI Pharmaceuticals brings isosorbide mononitrate generic (10 mg, 20 mg) to US market after FDA approval

ANI Pharmaceuticals has announced the launch of isosorbide mononitrate tablets USP in strengths of 10 mg and 20 mg after the FDA approved the abbreviated new drug application. The product is the generic version of the reference drug Monoket and is used to prevent chest pain in coronary heart disease. ANI most recently recorded revenue growth of 44% to $883 million over the last twelve months and earnings of $3.32 per share. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, ANI Pharmaceuticals has already paid 0,85€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, ANI Pharmaceuticals had revenue of 233,11M€ and net profit of 21,65M€

(EUR)	Jun 2026	YoY
Revenue	+233,11M	29,99%
Gross profit	+145,35M	25,27%
Net profit	+21,65M	198,52%
EBITDA	+52,90M	58,88%

Fundamentals

Metric	Value
Market capitalization	+1,46B€
Number of shares	22,73M
52-week high/low	+85,41€ - +60,21€
Dividends	No
Beta	0,46
P/E ratio	+15,44
PEG ratio	+0,01
P/B ratio	+2,64
P/S ratio	+1,73

Company profile

ANI Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das verschreibungspflichtige Markenarzneimittel und Generika in den Vereinigten Staaten und Kanada entwickelt, herstellt und vertreibt. Das Unternehmen konzentriert sich auf die Herstellung von kontrollierten Substanzen, onkologischen Produkten, Hormonen und Steroiden, injizierbaren Arzneimitteln und anderen Formulierungen. Das Unternehmen stellt orale Produkte in fester Dosierung, halbfeste, flüssige und topische Produkte sowie potente Produkte her und übernimmt die Auftragsentwicklung und -herstellung von pharmazeutischen Produkten für andere Unternehmen. Es vertreibt seine Produkte über Einzelhandelsapothekenketten, Großhändler, Distributoren und Versandapotheken sowie über Einkaufsgemeinschaften. Das Unternehmen wurde im Jahr 2001 gegründet und hat seinen Hauptsitz in Baudette, Minnesota.

Name	ANI Pharmaceuticals
CEO	Nikhil Lalwani
Headquarters	Baudette, mn USA
Website	anipharmaceuticals.com
Sector	Materials
Industry	Chemicals
IPO	03/19/2012
Employees	970